Clyburn and Maloney Issue Statement on Reports that 60 Million Doses of J&J Coronavirus Vaccine Made by Emergent BioSolutions Must Be Discarded
Jun 11, 2021
Washington, D.C. (June 11, 2021)—Today, Rep. James E. Clyburn, Chairman of the Select Subcommittee on the Coronavirus Crisis, and Rep. Carolyn B. Maloney, Chairwoman of the Committee on Oversight and Reform, issued the following statement after the Food and Drug Administration (FDA) announced that numerous batches—reportedly totaling 60 million doses—of the Johnson & Johnson coronavirus vaccine manufactured by Emergent BioSolutions, Inc. (Emergent) “are not suitable for use” due to contamination. An additional 60 million doses of the AstraZeneca coronavirus vaccine remain under review. FDA also announced that two additional batches of Johnson & Johnson vaccines manufactured by Emergent have been authorized for use in the United States and for export to other countries following the completion of extensive safety testing.
“Today’s news underscores our longstanding concerns regarding Emergent’s vaccine manufacturing practices and our previous findings that the company failed to address serious deficiencies at its Bayview facility despite repeated warnings. We are deeply troubled by the impact Emergent’s manufacturing errors has had on the number of vaccine doses available for global vaccination efforts and the potential effect on public perceptions regarding the safety and efficacy of these vaccines. Today’s news should not, however, deter those who have not yet received their vaccination. Coronavirus vaccines are safe and effective, and it is essential that everyone get vaccinated.”
“We will continue to investigate the lucrative vaccine manufacturing contracts Emergent received under the Trump Administration, the company’s failure to address the manufacturing problems that led to the destruction of tens of millions of life-saving vaccine doses, and how Emergent and its executives have profited despite these failures.”
On May 19, 2021, Chairwoman Maloney and Chairman Clyburn released initial findings from their investigation into Emergent, indicating that the failure to address serious deficiencies at Emergent’s Bayview facility led to the destruction of millions of doses due to contamination. At a Select Subcommittee hearing that same day, top Emergent executives acknowledged prior awareness of risks, but sought to downplay the contamination that occurred.